Related Experiment Video
Updated: Aug 25, 2025
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Case report: Blepharospasm in peak-dose dyskinesia may benefit from amantadine in Parkinson's disease
Qian-Ya Fan1, Xiao-Dong Zhang2, Ze-Di Hu3
1Department of Neurology, The First People's Hospital of Jiande, Hangzhou, China.
Introduction:
Blepharospasm is uncommon in Parkinson's disease, especially in the peak-dose dyskinesia period.
Case Presentation:
We herein present the case of a patient with PD who developed blepharospasm in the peak-dose dyskinesia period. The symptom was improved by taking amantadine.
Conclusion:
The current report expands the phenomenology of peak-dose dykinesia in PD to include dystonic blepharospasm. This complication of levodopa therapy may respond to amantadine despite the dystonic appearance of movements.
